LAURUS LABS
|
LAURUS LABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 2.93 | 14.56 | 15.40 | 18.33 | 23.88 |
| CEPS(Rs) | 10.26 | 20.81 | 20.17 | 22.16 | 8.28 |
| DPS(Rs) | 0.80 | 2.00 | 2.00 | 2.00 | 2.50 |
| Book NAV/Share(Rs) | 75.88 | 74.73 | 62.19 | 48.32 | 165.11 |
| Tax Rate(%) | 28.83 | 28.16 | 23.20 | 24.39 | 13.06 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.42 | 26.36 | 28.82 | 32.22 | 19.94 |
| EBIT Margin(%) | 8.32 | 21.09 | 24.03 | 28.45 | 13.53 |
| Pre Tax Margin(%) | 4.69 | 18.36 | 21.96 | 27.03 | 10.37 |
| PAT Margin (%) | 3.34 | 13.19 | 16.87 | 20.44 | 9.01 |
| Cash Profit Margin (%) | 10.97 | 18.55 | 21.96 | 24.70 | 15.63 |
| Performance Ratios | |||||
| ROA(%) | 2.10 | 10.89 | 13.09 | 20.87 | 7.34 |
| ROE(%) | 4.15 | 21.63 | 28.05 | 45.15 | 15.39 |
| ROCE(%) | 6.64 | 22.97 | 25.97 | 39.82 | 14.14 |
| Asset Turnover(x) | 0.63 | 0.83 | 0.78 | 1.02 | 0.81 |
| Sales/Fixed Asset(x) | 0.97 | 1.41 | 1.46 | 1.78 | 1.26 |
| Working Capital/Sales(x) | 6.98 | 5.87 | 7.44 | 7.79 | 23.66 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.04 | 0.71 | 0.69 | 0.56 | 0.79 |
| Receivable days | 117.42 | 88.66 | 98.37 | 79.52 | 96.76 |
| Inventory Days | 127.81 | 104.09 | 123.34 | 94.05 | 102.29 |
| Payable days | 135.42 | 106.10 | 175.76 | 155.37 | 145.69 |
| Valuation Parameters | |||||
| PER(x) | 133.90 | 20.12 | 38.31 | 19.75 | 2.70 |
| PCE(x) | 38.19 | 14.08 | 29.25 | 16.34 | 7.79 |
| Price/Book(x) | 5.16 | 3.92 | 9.49 | 7.49 | 1.95 |
| Yield(%) | 0.20 | 0.68 | 0.34 | 0.55 | 0.77 |
| EV/Net Sales(x) | 4.66 | 2.93 | 6.76 | 4.33 | 1.59 |
| EV/Core EBITDA(x) | 29.21 | 11.08 | 23.20 | 13.23 | 7.90 |
| EV/EBIT(x) | 56.00 | 13.90 | 28.12 | 15.21 | 11.75 |
| EV/CE(x) | 3.55 | 2.95 | 4.79 | 3.62 | 1.23 |
| M Cap / Sales | 4.19 | 2.61 | 6.42 | 4.04 | 1.22 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -16.55 | 22.39 | 2.54 | 69.99 | 23.55 |
| Core EBITDA Growth(%) | -49.70 | 11.16 | -8.68 | 175.97 | 53.30 |
| EBIT Growth(%) | -67.09 | 7.41 | -13.37 | 257.33 | 84.28 |
| PAT Growth(%) | -78.89 | -4.30 | -15.39 | 285.40 | 172.25 |
| EPS Growth(%) | -79.91 | -5.42 | -15.98 | -23.23 | 171.04 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.61 | 0.49 | 0.52 | 0.56 | 0.60 |
| Current Ratio(x) | 1.23 | 1.42 | 1.25 | 1.25 | 1.07 |
| Quick Ratio(x) | 0.64 | 0.73 | 0.59 | 0.61 | 0.54 |
| Interest Cover(x) | 2.29 | 7.71 | 11.59 | 20.09 | 4.28 |
| Total Debt/Mcap(x) | 0.12 | 0.12 | 0.05 | 0.07 | 0.31 |
Compare Financial Ratios of peers of LAURUS LABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LAURUS LABS | ₹29,424.2 Cr | -6.7% | -9.4% | 34.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹416,692.0 Cr | -5.3% | -7.8% | 24.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹149,215.0 Cr | -3.9% | -7.9% | 51% | Stock Analytics | |
| CIPLA | ₹115,000.0 Cr | -1.9% | -6.9% | 3.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,616.4 Cr | -8.3% | -14.9% | 0.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹93,841.4 Cr | -5.7% | -4% | 23.6% | Stock Analytics | |
LAURUS LABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LAURUS LABS | -6.7% |
-9.4% |
34.9% |
| SENSEX | 0.2% |
-2.2% |
7.7% |
You may also like the below Video Courses
